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Abstract
Background: Cognitive impairment is common in type 2 diabetes mellitus, and there is a strong association
between type 2 diabetes and Alzheimer’s disease. However, we do not know which type 2 diabetes patients will
dement or which biomarkers predict cognitive decline. Left ventricular hypertrophy (LVH) is potentially such a
marker. LVH is highly prevalent in type 2 diabetes and is a strong, independent predictor of cardiovascular events.
To date, no studies have investigated the association between LVH and cognitive decline in type 2 diabetes. The
Diabetes and Dementia (D2) study is designed to establish whether patients with type 2 diabetes and LVH have
increased rates of brain atrophy and cognitive decline.
Methods: The D2 study is a single centre, observational, longitudinal case control study that will follow 168 adult
patients aged >50 years with type 2 diabetes: 50% with LVH (case) and 50% without LVH (control). It will assess
change in cardiovascular risk, brain imaging and neuropsychological testing between two time-points, baseline
(0 months) and 24 months. The primary outcome is brain volume change at 24 months. The co-primary outcome is
the presence of cognitive decline at 24 months. The secondary outcome is change in left ventricular mass
associated with brain atrophy and cognitive decline at 24 months.
Discussion: The D2 study will test the hypothesis that patients with type 2 diabetes and LVH will exhibit greater
brain atrophy than those without LVH. An understanding of whether LVH contributes to cognitive decline, and in
which patients, will allow us to identify patients at particular risk.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12616000546459), date registered, 28/04/2016
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Background
Type 2 diabetes mellitus is associated with an increased
risk of dementia [1, 2] and more specifically, a two-fold
increase in the risk of Alzheimer’s disease [3]. Many fac-
tors may contribute to this strong association, including
increased stroke incidence, white matter microstructural
changes, hyperinsulinaemia and metabolic syndrome, as
well as the cross-association of mid-life obesity and type
2 diabetes [4]. A diagnosis of diabetes in midlife in-
creases the risk of both vascular cognitive impairment
and Alzheimer’s disease [5].
Magnetic resonance imaging (MRI) markers of struc-
tural brain aging such as reduced total brain volume,
cortical thickness, hippocampal volume, and increasing
white matter hyperintensity load, are correlated with
performance on neuropsychological tests and are power-
ful predictors of dementia [6, 7]. A strong association
between midlife vascular risk factors and structural brain
aging has been demonstrated [8], although longitudinal
brain volume changes have not been thoroughly exam-
ined in patients with type 2 diabetes. The PROSPER
study findings suggested that elderly non-demented pa-
tients with type 2 diabetes had accelerated progression
of brain atrophy compared to non-diabetic individuals
and provided evidence for the hypothesis that diabetes
exerts deleterious effects on neuronal integrity [9].
There is little evidence that intensive glycaemic man-
agement as reflected by lower HbA1c levels in type 2
diabetes is associated with reduced dementia risk [10, 11]
or cognitive decline [12]. The ACCORD-MIND study
investigators [10] found no evidence that an intensive
glycaemic treatment strategy targeting HbA1c to <6%
altered cognitive outcomes in patients with type 2
diabetes. However, the ACCORD study was halted
due to higher mortality rates from cardiovascular
events in the intensive arm [13]. Subsequent follow-
up of the ACCORD-MIND participants found an as-
sociation between poor cognitive function and the
risk of severe hypoglycaemic events [14]. A further
80 months of follow-up in the ACCORDION MIND
trial showed no long term benefits of intensive gly-
caemic control on cognition or brain MRI outcomes
[15]. It therefore remains unclear if tight glycaemic
control as reflected by lower HbA1c levels lead to
lower risk of dementia and better biomarkers are
needed for the prediction of cognitive decline to
stratify the risk of dementia in type 2 diabetes.
Patients with type 2 diabetes have associated hyper-
tension [16], a high prevalence of previously unknown
heart failure [17] and left ventricular dysfunction [17, 18].
Left ventricular hypertrophy (LVH) is also highly
prevalent in patients with type 2 diabetes [18] and
hypertension [19] and is an established independent
predictor of adverse cardiovascular outcomes, including
stroke [20] and heart failure [21]. Patients with type 2
diabetes and co-morbid hypertension have increased
left ventricular mass, more concentric left ventricular
geometry, lower myocardial function, that is inde-
pendent of age, sex, body size, arterial blood pressure
and atherosclerosis, compared to hypertensive individ-
uals without type 2 diabetes [16]. Diabetes and hyperten-
sion predispose to the ischemic small vessel disease
underlying lacunar infarction. Lacunar infarction can
result in cognitive decline from selective damage to
frontal-subcortical circuits subserving processing speed
and executive function, and these deficits are often ob-
served in type 2 diabetes [22].
There is a strong association between cardiac disease
and impairment across many cognitive domains, particu-
larly in tests of executive function [23]. Heart failure is
strongly associated with cognitive impairment [24–26]
and is an independent risk factor for the development of
Alzheimer’s disease and cerebrovascular disease [16].
Carotid atherosclerosis is associated with cognitive im-
pairment [27], measures of structural brain aging [8] and
reductions in parietal gray matter [8]. LVH is associated
with progressive cognitive decline, independent of blood
pressure and large artery stiffness [28]. Left ventricular
mass is associated with worse performance on tests of
both visuospatial and verbal memory [29], and there is a
nonlinear association between left ventricular ejection
fraction (EF) and measures of accelerated structural and
cognitive brain aging [30].
The D2 (diabetes and dementia) study
The diabetes and dementia study (D2) study is an ob-
servational study in which we will intensively study the
cardiovascular status of patients with type 2 diabetes
and investigate if LVH predicts cognitive function, or if
specific cardiac indices predict cognitive decline and
brain atrophy. We will recruit participants with type 2
diabetes and integrate transthoracic echocardiography,
carotid imaging, brain imaging with MRI, circulating
and genetic biomarkers, and neuropsychology tools, to
establish the relationship between type 2 diabetes,
brain atrophy, and cognitive decline in a cohort of 168
individuals with and without LVH. At baseline, all
participants will have structural neuroimaging with
MRI to assess global brain volume, regional cortical
thickness and hippocampal volume, a 12 lead electro-
cardiogram (ECG), an echocardiogram to assess the
absence or presence of LVH, a carotid ultrasound to
assess vascular disease, 24-h ambulatory blood pres-
sure and ECG, cognitive assessment, and apolipopro-
tein E (APOE) gene risk assessment. All of the
aforementioned assessment tools will be repeated at
the 24-month follow up period.
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Methods
The D2 study has been approved by the Human Research
Ethics Committee at Austin Health (HREC/15/Austin/
490) and is registered at the Australian New Zealand Clin-
ical Trials Registry (ACTRN12616000546459). Funding
is provided through the National Health and Medical
Research Council of Australia (APP1094974). Informed
written consent is obtained from the participants prior
to any data collection.
D2 Study design
The D2 study is a single center, observational, longitu-
dinal, case-control study. One hundred and sixty-eight
adult patients, aged greater than 50 years with type 2
diabetes will be followed: 50% with LVH (case) and 50%
without (control). Patients will be assessed at baseline
(0 months) and will return for tests at the 24 month
time-point. Based on recruitment in our other diabetes,
cognitive and imaging trials, it is expected that 80–90
patients will be recruited annually for the first 2 years.
Recruitment of new patients will be completed at the
end of 2 years, allowing the next 2 years for follow-up.
Study hypotheses
1. Patients with type 2 diabetes and LVH will exhibit
greater brain atrophy as assessed by MRI structural
changes than those without LVH.
2. Brain atrophy as assessed by MRI structural changes
will be associated with worse cognitive performance.
3. Increased left ventricular mass with specific left
ventricular geometric patterns will be associated
with the most severe regional brain atrophy and
cognitive decline.
Study aims
1. To establish whether diabetic patients with LVH
have increased rates of brain atrophy and cognitive
decline.
2. To establish whether the specific LV geometric
measures are associated with these brain volume
changes.
Study outcome measures
Our primary endpoint is brain volume change at 2 years
(hypothesis 1). Our co-primary outcome is the pres-
ence of cognitive decline at 2 years (hypothesis 2). We
shall use advanced brain imaging to accurately measure
brain volume and correlate this with cardiac echocardi-
ography, carotid intima media thickness (CIMT), and
24 h blood pressure and ECG monitoring in 168 pa-
tients with type 2 diabetes, with longitudinal testing
allowing measurement of change at 24 months.
Concurrent neuropsychological testing will indicate
whether the clinical profile of cognitive impairment
and dementia aligns with measures of brain volume.
Eligibility criteria
Inclusion criteria are as follows: (1) aged over 50 years;
(2) no prior neurological or psychiatric disease, including
stroke; (3) ability to give informed consent and partici-
pate in cognitive testing. The study exclusion criteria are
as follows: (1) known prior stroke, transient ischemic at-
tack or dementia; (2) significant medical co-morbidities
precluding participation in cognitive testing, or making
survival for 24 months unlikely; (3) normal exclusion
criteria for MRI; e.g., implanted metal, severe claustro-
phobia; (4) severe diabetic nephropathy: estimated glom-
erular filtration rate (eGFR <30 mL/min/1.73 m2).
Study assessments
The schedule of assessments is provided in Table 1.
Testing will include the following: a pre-study screening
questionnaire and MRI safety check to determine eligi-
bility; demographic and medical history questionnaire;
clinic measurement of height, weight, waist and hip;
echocardiogram, ECG; CIMT; 24 h ambulatory blood
pressure and ECG monitor; cognitive assessment; MRI
scan; physical activity monitor; and a blood sample (to
determine APOE genetic risk and analyses of genetic
and plasma/serum biomarkers).
Details of questionnaire and measurements
Pre-study screening and MRI safety check questionnaires
A short questionnaire will be used to ask questions re-
lated to the study eligibility, which will be key to iden-
tifying patients that may be unsuitable for MRI testing.
Those identified as unsuitable will be informed at this
stage and no further measurements will be conducted.
Eligible participants will complete a detailed MRI
safety questionnaire with the investigator to obtain
more specific information about their history of surgi-
cal procedures to determine whether they have im-
plants that might not be suitable for a 3 T MRI scan.
Participants will be excluded if they cannot have a re-
search 3 T MRI scan (e.g., because they have a metal
implant that has not been cleared for safety in a 3 T
MRI scanner).
Demographic and medical history questionnaire
A questionnaire and medical record review will be con-
ducted at the time of the echocardiogram and blood
collection. The following information will be collected:
age, sex, duration of diabetes, smoking history, alcohol
consumption, current drug therapy and dose, socioeco-
nomic status family history of cardiovascular disease,
medical history including general health and co-
Patel et al. BMC Endocrine Disorders  (2017) 17:24 Page 3 of 9
morbidities (cardiac disease, hypertension, dyslipidae-
mia, the presence of micro-vascular disease (nephropa-
thy, retinopathy, neuropathy) and other macro-vascular
complications (peripheral vascular disease). The ques-
tionnaire will be cross-checked by medical record
review at Austin Health, and from their clinical and
specialist reports if recruited outside of Austin Health.
Physical measurements
Participants’ height and weight (to determine body
mass index (BMI) and body surface area) will be
assessed. Weight will be measured to the nearest 0.1 kg
on standing digital scales without shoes and light cloth-
ing. Height will be measured using a wall-mounted
stadiometer to the nearest 0.1 cm. Waist and hip cir-
cumferences will be measured using a spring loaded
tape. Waist circumference is measured at the mid-point
between the lower costal margin and the iliac crest. Hip
circumference is measured over the greater trochanters.
Transthoracic echocardiography (TTE)
TTE will be performed by a cardiologist using a commer-
cially available portable ultrasound system (Vivid i, GE
Healthcare). Standard parasternal and apical views will be
used to assess left ventricular mass. Measurements are
obtained according to the American Society of Echocardi-
ography (ASE) recommendations [31]. M-mode echo will
be used to measure cardiac dimensions and wall thickness.
Ejection fraction will be calculated using the modified
Simpson’s rule. Left ventricular mass will be indexed using
the ASE corrected convention, by dividing left ventricular
mass by height2.7. LVH will be defined as >49 g/m2.7 for
males and >45 g/m2.7 for females. Relative wall thickness
will be calculated, and left ventricular remodelling classi-
fied as normal, eccentric, or concentric remodelling and
concentric LVH.
Blood collection and measurements
Fasting plasma electrolytes, glucose, HbA1C, lipids and
urinary analyses will be obtained on all patients at base-
line and at 24 months. The D2 study will collect add-
itional plasma, serum and whole blood for genetic
analyses. The exploration of novel circulating biomarkers
and genetic determinations that lead to LVH and/or
brain atrophy will be conducted within our laboratory.
Whole blood will be collected and divided between lith-
ium heparin and EDTA tubes for plasma and genetic
samples and a plain tube for serum. Serum will be ex-
tracted and aliquoted for storage at -80 °C until assayed.
For plasma, the sample tube will be stored on ice and
Table 1 Schedule of assessments at baseline (0 months) and 24 months
Assessments Brief description Time-point (months)
0 24
Pre-study screening questionnaire
(to determine study eligibility)
Study eligibility criteria ✓
MRI safety check questionnaire MRI eligibility ✓ ✓
Demographic and medical history questionnaire Questionnaire completed with the study investigator ✓ ✓
Weight, height, waist and hip measurement Clinical assessment ✓ ✓
Transthoracic echocardiogram Assess cardiac structure and function ✓ ✓
Blood sample Plasma electrolytes, glucose, HbA1C, lipids and urinary analyses.
Blood collected for APOE genotyping and assessment of other
genetic and circulating biomarkers.
✓ ✓
Carotid intimal medial thickness B-mode ultrasound to assess left and right internal carotid arteries
and the degree of stenosis
✓ ✓
24 h ambulatory blood pressure and ECG Holter Simultaneous measurement of blood pressure and ECG ✓ ✓
MRI scanning on a Siemens 3 T Skyra scanner
using a 64 Channel receive only head coil.
• High resolution isotropic T1 3D MPRAGE (structural scan) ✓ ✓
• High resolution isotropic T2 FLAIR 3D
• High resolution isotropic T2 3D
• Susceptibility-weighted image (SWI) for iron deposition
• Diffusion-weighted imaging (DWI)
• GRE field mapping
• BOLD 7 min free run (resting state connectivity)
Cognitive and mood evaluation Validated tools for assessing mood, global cognitive ability,
attention, visuospatial ability, executive function, language,
memory, processing speed
✓ ✓
Physical activity assessment SenseWear Armband (BodyMedia FIT) ✓ ✓
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centrifuged within 15 min to separate the plasma. The
plasma will be aliquoted for storage at -80 °C until
assayed. Whole blood will be collected in a potassium
EDTA tube and immediately stored at -80 °C until DNA
extraction. APOE genotyping will be performed in our
laboratory. Genomic DNA will be extracted using the
Qiagen DNA Maxi kit (Qiagen, Germany) and the APOE
region of interest will be amplified with specific primers.
The resulting DNA fragment will be sequenced in the
forward and reverse direction on an ABI 3130-xl genetic
analyser (Applied Biosystems, CA, USA). Participants
will be informed of their APOE ε4 status by the Principle
Investigator and those with APOE ε4 homozygosity will
be offered counselling via the Neurogenetics Clinic at
Austin Health.
Carotid Doppler ultrasound
CIMT measurements will be conducted in the Neur-
ology diagnostics laboratory, Austin Health by a single
technician. High-resolution B-mode ultrasound images
will be obtained on both right and left internal carotid
arteries. CIMT will be measured, and the degree of sten-
osis will also be classified into accepted clinical grades
for incorporation into multivariate analyses: none, <50%,
50–69%, 70–79%, 80–89%, 90–99% and occluded (NAS-
CET criteria) [32].
Ambulatory blood pressure and ECG monitoring
Each participant will have a combined Holter monitor
simultaneously assessing ambulatory blood pressure and
ECG data (CardXplore, Meditech, Hungary).
MRI acquisition and processing
Scans will be acquired for gray and white matter anatom-
ical, structural and functional connectivity and iron esti-
mation analyses. High resolution structural MRI of study
subjects will be acquired using a 3 T Siemens Skyra MR
scanner. The following sequences will be acquired: T1-
weighted three-dimension (3D) magnetization-prepared
rapid gradient-echo (MP-RAGE) for anatomical analyses;
susceptibility-weighted image (SWI) for iron estimation
and microhemorrhage imaging; fluid-attenuated inversion
recovery (FLAIR) to assess chronic white matter ischemic
changes and diffusion weighted imaging (DWI) to assess
white matter structural integrity.
Regional cortical gray matter atrophy will be assessed
using vertex-wise cortical thickness analysis. Cortical
thickness will be mapped using the FreeSurfer software
package for analysis of structural MRI data (http://surfer.
nmr.mgh.harvard.edu/fswiki) [33]. The automated cor-
tical and subcortical parcellation routines also provided
with FreeSurfer will be used to investigate regional
volume changes. We will use processing streams devel-
oped specifically by our group for longitudinal studies
[34, 35]. Hippocampal volume changes will be assessed
using manual hippocampal segmentation. Iron depos-
ition and cerebral microbleeds will be assessed with
susceptibility-weighted image analyses. The MRI proto-
col is provided in the Additional file 1.
Cognitive and mood assessment questionnaire and tests
Participants will complete a neuropsychological assess-
ment. The assessment will include several paper-and-
pencil and computerized cognitive tasks and mood
questionnaires. Six cognitive domains will be examined,
including (i) attention, (ii) visuospatial ability, (iii) ex-
ecutive function, (iv) language, (v) memory, and (vi)
processing speed. The tasks used to measure each cog-
nitive domain are listed in Table 2. This protocol has
been modelled on that validated by the CANVAS study,
a longitudinal study of patients after stroke [36]. All
tasks are designed for serial testing and are less affected
by practice effects. Performance on individual cognitive
tests will be standardised using established norms and
domain scores will be calculated by averaging the stan-
dardised scores from each contributing test (e.g., Trail
Making Test as a measure of attention). Assessment of
mood will be completed using the seven-item General-
ized Anxiety Disorder (GAD-7) questionnaire and the
nine-item Patient Health Questionnaire (PHQ-9).
These questionnaires are based on criteria for the diag-
nosis of generalised anxiety and depression (Diagnostic
and Statistical Manual-Fourth Edition: DSM-V) [37].
Physical activity monitoring
The SenseWear Pro2 Armband (HealthWear BodyMedia,
Pittsburgh, PA, USA) is a portable device which enables
monitoring of energy expenditure and activity. The device
uses a two-axis accelerometer, a heat flux sensor, a gal-
vanic skin response sensor, a skin temperature sensor, and
a near-body ambient temperature sensor to capture data
and will be worn by each participant on the upper arm for
7 days. The data will be converted into Metabolic Equiva-
lents minutes (METs*minutes) and energy expenditure
using an algorithm (Bodymedia, Sense Wear 6.1) [38].
The SenseWear monitor has been validated for measuring
energy expenditure in diabetes against double-labeled
water [39].
Sample size
We aim to recruit 168 patients with type 2 diabetes. Pa-
tients will be divided based on the presence of LVH.
Higher left ventricular mass and concentric geometric
changes have been demonstrated in approximately 35–
40% of patients with type 2 diabetes [16, 17]. Our data
suggested more than 50% of participants will have
LVH [18]. We calculated our sample size in order to
include sufficient participant numbers for both the
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primary endpoint comparison (brain volume) and for
the primary outcome measure (presence of cognitive
impairment). The primary endpoint requires a direct
comparison of two groups: type 2 diabetes patients
with LVH and those without. We based our effect
size on published brain volume and cortical thickness
estimates performed on healthy controls, cerebrovas-
cular disease patients and Alzheimer’s disease patients
[40–42], and prior imaging of healthy controls and
stroke patients performed by our group [43]. We use
an average brain volume change of <0.5% per annum
for controls, 1–2% for cerebrovascular disease, and 2–
4% for dementia [44].
We used a modified retrospective case-control method.
All participants have the exposure (type 2 diabetes),
which will naturally halve by the additional risk factor
(LVH, expected prevalence around 50%), but only some of
them will develop the primary outcome (cognitive de-
cline). We used an ANCOVA method to estimate sample
size for four samples (cognitively impaired LVH, non-
cognitively impaired LVH, cognitively impaired non-LVH,
non-cognitively impaired non-LVH) with repeated mea-
sures, including a correlation score between baseline and
follow-up. Using alpha = 0.05 (two-sided), power = 0.8 and
an estimated correlation of 0.1, we estimated that 140 (i.e.,
35 in each of 4 groups) participants will be required.
Given we expect around 20% attrition due to death or
non-participation (unable to participate in testing due to
new pacemaker/implanted metal/other medical issue, lost
to contact, no longer interested), we have estimated a total
recruitment number of 168. This model has used the
conservative estimates from these results and assumes
the following: that 30% of patients will be cognitively
impaired at 2 years; a 1% total annual brain volume
change for patients with type 2 diabetes; that 30% of
patients will exhibit specific left ventricular geometric
changes; and a low correlation between baseline and
follow-up measures.
Statistical analysis
The analysis of this study will be performed in three
parts as follows.
Hypothesis 1: comparing brain volumes between
participants with and without LVH. Independent
samples t-tests will be used to determine differences
between participants with and without LVH at each
time-point. Repeated-measures t-tests will be used to
determine the extent of brain volume loss across the
two time-points. These results will be compared
between groups. In the cortical thickness analyses, the
large number of statistical inferences being carried
out across the cortical sheet (approximately 160,000
vertices per hemisphere) requires adjustment of the
statistical threshold. This is to control for the increased
number of false positive findings using false discovery
rate correction procedure widely used for cortical
thickness analyses. In the volumetric analyses, total
brain volume, regional white matter, cortical and
subcortical volume changes will be modelled using a
repeated measures design. Intracranial volume, which
is determined partially by gender and race, is a known
confounding factor that contributes to regional brain
volumes. This will be controlled for in the statistical
analysis of regional brain volume change. We have
demonstrated this to be a reliable index of brain
volume in previous studies [43].
Hypothesis 2: correlating brain volume with
cognitive performance. The initial regressive analysis
will examine differences between cognitively impaired
and normal participants at 2 years. We will correlate
both global and regional measures of brain volume
with the groups. Global brain and regional
hippocampal volumes, and mean regional cortical
thickness values for the stated regions of interest will
be compared between two groups, in order to correlate
LVH-associated brain volume changes with cognition.
We will also perform a multivariate analysis across the
cohort as a whole to investigate whether there is a
dose-related association with any extent of cardiac
impairment. Multivariate regression will be conducted
to determine whether brain volume loss correlates
with the presence or absence of cognitive impairment,
Table 2 Tasks used to measure each cognitive domain
Cognitive domain Cognitive task
Global Cognitive Ability Montreal Cognitive Assessment [45]
The Clinical Dementia Rating [46]
National Adult Reading Task [47]
Attention Trail-Making Test [48]
Digit Span Task (WAIS-IV) [49]
Identification Task (Computerised
CogState battery) [50]
One Back Task (Computerised) [50]
CogState battery)
Visuospatial Ability Rey Complex Figure Test (Copy) [51]
Executive Function Clock Drawing Task – CLOX [52]
Controlled Oral Word Association Test [53]
Language 30-item Boston Naming Test [54]
Verbal Fluency Test [53]
Memory Rey Auditory Verbal learning Task [55]
Rey Complex Figure Test (Recall) [51]
Processing Speed Detection Task (Computerized
CogState battery) [50]
Digit-Symbol Task (WAIS-IV) [49]
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adjusting for known important variables such as age,
years of education, CIMT, atrial fibrillation, cholesterol
and hypertension, as well as potentially relevant
variables including APOE ε4 status, cardiac indices
such as stroke volume, renal function and HbA1c levels.
Hypothesis 3: comparing brain volume and
cognitive performance in participants with
increased left ventricular mass and specific left
ventricular geometric patterns. Analysis will be
similar to that for LVH, except that patients will be
divided on the presence or absence of specific
morphometric measures. That is, analyses will be
performed at each time-point (cross-sectional), and
also longitudinally, to investigate change across time.
Repeated-measures t-tests will determine the extent
of brain volume loss across the two time-points and
compared between groups. Correlation with cognitive
performance will be performed as above. Unadjusted
differences for clinical variables between groups will be
assessed by t-test. Difference in laboratory data and
left ventricular systolic function will be adjusted for
age and sex by use of ANCOVA. Differences in left
ventricular structure and geometry will be adjusted
for age, sex, BMI, and systolic blood pressure as their
major established covariates with further adjustment
for duration of hypertension. Fisher’s Exact Test and
odds ratios will be used to test differences for categorical
variables. Logistic regression analysis will be used to
derive odds ratios adjusted for covariates. Multiple
regression analyses will be performed to assess relation
of cognitive and brain volume measures to higher left
ventricular mass independent of established covariates
and duration of hypertension.
Discussion
The D2 study will aim to improve the understanding of
two of the major causes of death, disability and reduced
quality of life in our society: diabetes and dementia. In
an ageing population, it is vitally important that we in-
crease our knowledge of the relationships between car-
diovascular disease and cognition. We have the means
to identify a potentially treatable risk factor in the caus-
ation of cognitive impairment. The study will provide
unique information on the relationship between LVH
and dementia in type 2 diabetes, and whether cardiac
structural and functional abnormalities contribute to in-
creased brain atrophy and cognitive impairment. Brain
volume changes may precede cognitive changes, provid-
ing a potential for early diagnosis and intervention. A
large proportion of these patients may have associated
or superadded Alzheimer’s pathology. These patients
provide a high risk cohort requiring urgent intervention
to prevent increasing dependence and disability. The
identification of people at risk of cognitive impairment
and dementia will allow for both secondary prevention
and early intervention. With the advent of aggressive
risk management strategies for cardiovascular disease,
identification of these patients will allow them to be
treated early in their disease course, ideally before they
develop cognitive decline.
Additional file
Additional file 1: D2 Study MRI: Data acquired on a Siemens 3 T Skyra
scanner using a 64 Channel receive only head coil. (DOCX 12 kb)
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